Aardvark Therapeutics (NASDAQ:AARD) Earns Overweight Rating from Analysts at Morgan Stanley

Stock analysts at Morgan Stanley started coverage on shares of Aardvark Therapeutics (NASDAQ:AARD) in a research note issued to investors on Monday,Briefing.com Automated Import reports. The brokerage set an “overweight” rating and a $29.00 price target on the stock. Morgan Stanley’s target price suggests a potential upside of 186.28% from the company’s previous close.

A number of other research firms have also commented on AARD. Royal Bank of Canada initiated coverage on shares of Aardvark Therapeutics in a research report on Monday. They set an “outperform” rating and a $21.00 price target for the company. Bank of America started coverage on shares of Aardvark Therapeutics in a report on Monday. They issued a “buy” rating and a $22.00 price objective on the stock. Finally, Cantor Fitzgerald began coverage on shares of Aardvark Therapeutics in a research report on Monday. They set an “overweight” rating and a $50.00 price objective on the stock.

Aardvark Therapeutics Trading Up 6.4 %

Shares of AARD opened at $10.13 on Monday. Aardvark Therapeutics has a one year low of $9.21 and a one year high of $19.58.

Insider Buying and Selling at Aardvark Therapeutics

In related news, CEO Tien-Li Lee acquired 16,542 shares of the firm’s stock in a transaction on Friday, February 14th. The shares were acquired at an average cost of $16.00 per share, with a total value of $264,672.00. Following the completion of the acquisition, the chief executive officer now directly owns 1,496,175 shares in the company, valued at approximately $23,938,800. This trade represents a 1.12 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CFO Nelson Sun acquired 10,000 shares of the firm’s stock in a transaction on Friday, February 14th. The shares were bought at an average cost of $16.00 per share, for a total transaction of $160,000.00. Following the completion of the acquisition, the chief financial officer now owns 99,484 shares of the company’s stock, valued at approximately $1,591,744. This represents a 11.18 % increase in their ownership of the stock. The disclosure for this purchase can be found here.

Aardvark Therapeutics Company Profile

We are a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. We target biological pathways associated with alleviating hunger that we believe have the potential to deliver transformative outcomes for patients.